[Metabolomics and thyroid cancers: new approaches for biomarkers discovery]

ABSTRACT

Introduction: Thyroid cancer is the most common malignancy of endocrine systems. Nowadays, Fine Needle Aspiration Biopsy [FNAB] is the gold standard in the diagnosis of thyroid cancers. Despite the high accuracy of this method, roughly 20-30 % of patients have indeterminate cytological results and surgery [histo pathological examination] is required for final confirmation of malignancy, a limitation, for which the need to provide a non-invasive approach seems necessary. Metabolomics is the study of a complete set of metabolites in biologic samples and compared to normal cells, metabolites in cancer cells show alterations. This article reviews the role of metabolomics i.e studies in the discrimination and diagnosis of thyroid cancers